NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

HIQA assessment supports current GEP test for breast cancer

By Reporter - 17th Feb 2023


A Health Information and Quality Authority (HIQA) report has backed the current use of a gene expression profiling (GEP) test in Ireland but calls for more data and guidance regarding the use of other tests.

HIQA published a rapid health technology assessment on GEP tests for breast cancer at the request of the HSE’s National Cancer Control Programme. GEP tests are performed on tumour samples from early-stage breast cancer patients to help decide if they would benefit from chemotherapy after their surgery.

According to HIQA currently, the HSE covers the cost of one GEP test called Oncotype DX®. The costs of other tests are not covered. HIQA’s rapid HTA looked at the evidence for all four tests that are currently commercially available in Ireland to provide advice to the HSE on the alternatives to Oncotype DX®.

“HIQA looked at different groups of breast cancer patients who are eligible to receive GEP tests,” the Authority said in a statement. “For people with cancer that has spread to their lymph nodes, the test with the strongest evidence was Oncotype DX®. For people with cancer that had not spread to their lymph nodes the data was more limited; however, the available evidence supported the continued use of Oncotype DX®.”

HIQA noted that any decision on whether to cover the cost of GEP tests other than Oncotype DX® should also take into account differences in factors such as which patient groups a test can be used in, the cost and the practicality of their use in Ireland.

Ms Shelley O’Neill, Deputy Director of HTA at HIQA, said: “Going through breast cancer treatment is extremely tough and while chemotherapy has contributed to declining breast cancer mortality, it has short- and long-term side effects. Some people may not benefit from chemotherapy. GEP tests can help identify those who may not need to go through chemotherapy and this would provide benefits for both the patient and the health system.”

Ms O’Neill continued: “We found that there is a need for greater data on GEP test use in Ireland that would allow us to fully assess the use of these tests in the future. It may also be helpful to develop guidance on test use and on understanding the test results so that we can best optimise the use of GEP testing.”

Leave a Reply

Latest Issue
The Medical Independent 20th February
The Medical Independent 20th February 2024

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read